Status:
TERMINATED
Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT
Lead Sponsor:
National Cerebral and Cardiovascular Center, Japan
Collaborating Sponsors:
Ministry of Health, Labor and Welfare (Japan)
Conditions:
Impaired Glucose Tolerance
Myocardial Infarction
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate whether an alpha-glucosidase inhibitor, a drug for the suppression of postprandial hyperglycemia, could reduce the recurrence of myocardial infarction in patie...
Detailed Description
Type 2 diabetes mellitus is a well-established risk factor for coronary heart disease and atherosclerotic change in the coronary artery develops subclinically in a state of impaired glucose tolerance ...
Eligibility Criteria
Inclusion
- Impaired glucose tolerance
- History of myocardial infarction
Exclusion
- Type I diabetes
- History of coronary artery bypass graft
- Severe liver and/or kidney dysfunction
- History of allergic response to drugs
- Arteriosclerosis obliterans
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT00212017
Start Date
April 1 2005
End Date
August 1 2017
Last Update
August 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cardiovascular Center
Suita, Osaka, Japan, 565-8565